Form 13-F position report

* ALEXION PHARMACEUTICALS INC

Reported by GLG Partners LP

ALXN CUSIP 015351109 Manager CIK 0001289643

Reported 260,323 shares, up 25,313 (10.8%) from the prior quarter.

Reported value -19.2%; share count 10.8% vs. the prior quarter.

Added
% of reported 13F value 1.03% This manager · Q1 2016
Shares 260,323 Quarter-end amount reported
Reported value $36,242,000 Fair value at quarter end
Consecutive quarters held 4 Through Q1 2016

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2015-06-30 6869000
2015-09-30 35997000
2015-12-31 44828000
2016-03-31 36242000
2016-06-30 19938000
2016-09-30 7884000
2016-12-31 0
2017-03-31 566000
2017-06-30 1489000
2017-09-30 313000
2017-12-31 1148000

Quarterly position history

How this manager's reported quarter-end position changed over time.

11 quarters
Quarterly reported position history for * ALEXION PHARMACEUTICALS INC held by GLG Partners LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2017 Added 9,602 +7,369 (330.0%) 0.05% $1,148,000 2018-02-14
Q3 2017 Reduced 2,233 -10,001 (-81.7%) 0.02% $313,000 2017-11-14
Q2 2017 Added 12,234 +7,567 (162.1%) 0.08% $1,489,000 2017-08-14
Q1 2017 New 4,667 +4,667 (0.0%) 0.03% $566,000 2017-05-15
Q4 2016 Reduced 0 -64,341 (-100.0%) 0 $0 2017-02-14
Q3 2016 Reduced 64,341 -106,420 (-62.3%) 0.24% $7,884,000 2016-11-14
Q2 2016 Reduced 170,761 -89,562 (-34.4%) 0.6% $19,938,000 2016-08-16
Q1 2016 Added 260,323 +25,313 (10.8%) 1.03% $36,242,000 2016-05-16
Q4 2015 Added 235,010 +4,834 (2.1%) 1.43% $44,828,000 2016-02-16
Q3 2015 Added 230,176 +192,176 (505.7%) 0.95% $35,997,000 2015-11-16
Q2 2015 New 38,000 +38,000 (0.0%) 0.18% $6,869,000 2015-08-14

Who else reported the position

475 managers reported * ALEXION PHARMACEUTICALS INC for Q1 2016.

Managers reporting * ALEXION PHARMACEUTICALS INC in Q1 2016.
Manager Activity Shares Change % of reported 13F Reported value Tenure
PRICE T ROWE ASSOCIATES INC MD Reduced 28,214,386 -81,041 0.84% $3,928,007,000 12 qtrs
Capital Research Global Investors Unchanged 27,602,207 0 1.32% $3,842,779,000 12 qtrs
FMR LLC Added 16,743,710 +1,864,885 0.32% $2,331,060,000 12 qtrs
VANGUARD GROUP INC Added 13,262,449 +288,491 0.12% $1,846,399,000 12 qtrs
STATE STREET CORPORATION Reduced 8,786,752 -30,932 0.13% $1,223,291,000 2 qtrs
JENNISON ASSOCIATES LLC Reduced 7,310,127 -35,897 1.07% $1,017,716,000 12 qtrs
BAKER BROS ADVISORS LP Unchanged 6,542,599 0 9.61% $910,861,000 4 qtrs
BlackRock Institutional Trust Company N A Added 5,601,869 +15,733 0.13% $779,892,000 12 qtrs
AMERIPRISE FINANCIAL INC Added 5,297,593 +92,063 0.44% $737,529,000 12 qtrs
SANDS CAPITAL MANAGEMENT LLC Reduced 5,211,879 -844,883 2.14% $725,598,000 12 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2016
Filed
May 16, 2016
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
260,323
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.